Bupivacaine Spinal Tung Aguettant: Uses, Dosage & Side Effects

What Is Bupivacaine Spinal Tung Aguettant and What Is It Used For?

Bupivacaine Spinal Tung Aguettant contains the active substance bupivacaine hydrochloride, an amide-type local anesthetic that has been one of the most widely used agents for spinal anesthesia since its introduction into clinical practice in the 1960s. Bupivacaine belongs to the same chemical family as lidocaine and ropivacaine but is distinguished by its longer duration of action and its particular suitability for spinal (intrathecal) administration. The “Tung” in the product name refers to the Swedish/Nordic pharmaceutical term for “heavy” (hyperbaric), indicating that this formulation is denser than normal cerebrospinal fluid (CSF).

The hyperbaric nature of this formulation is achieved by the addition of glucose (dextrose) at a concentration of 80 mg/ml. This gives the solution a specific gravity of approximately 1.026 at 37°C, compared to the specific gravity of CSF which is approximately 1.003–1.009. This density difference is critically important in clinical practice because it means that when the solution is injected into the subarachnoid space, it will sink under the influence of gravity relative to the surrounding CSF. This physical property allows the anesthesiologist to control the distribution and final level of the spinal block by positioning the patient appropriately on the operating table during and immediately after injection — a technique known as gravitational control of block spread.

Bupivacaine works by reversibly blocking voltage-gated sodium channels in the membranes of nerve cells. When injected into the intrathecal space, it comes into direct contact with the spinal nerve roots and the surface of the spinal cord. By preventing sodium ions from flowing through nerve cell membranes, bupivacaine blocks the generation and propagation of electrical impulses (action potentials) along nerve fibers. This produces a reversible interruption of nerve conduction, affecting sensory (pain and temperature), motor (muscle movement), and autonomic (blood vessel tone and organ function) nerve pathways. The blockade is concentration-dependent and follows a differential pattern: autonomic fibers are blocked at the lowest concentrations, followed by sensory fibers, and finally motor fibers at the highest concentrations.

Bupivacaine Spinal Tung Aguettant is indicated for surgical anesthesia of the lower body when a spinal (subarachnoid) block is appropriate. Common surgical applications include:

• Cesarean section: One of the most common applications worldwide, providing rapid and reliable anesthesia for both elective and urgent cesarean deliveries. Hyperbaric bupivacaine is the preferred agent for obstetric spinal anesthesia in most international guidelines.
• Orthopedic surgery of the lower limbs: Including total hip replacement, total knee replacement, arthroscopic knee surgery, ankle fracture fixation, and lower limb amputations. The duration of action is typically sufficient for most standard orthopedic procedures.
• Urological procedures: Such as transurethral resection of the prostate (TURP), transurethral resection of bladder tumors, cystoscopy, and other lower urinary tract procedures. Spinal anesthesia allows the patient to remain awake, which can be advantageous for detecting early signs of TURP syndrome.
• Hernia repair: Inguinal and femoral hernia repairs, where spinal anesthesia provides excellent operating conditions with good muscle relaxation.
• Lower abdominal surgery: Including appendectomy, lower bowel surgery, and gynecological procedures such as hysterectomy and laparoscopic procedures.
• Perineal and perianal surgery: Such as hemorrhoidectomy, anal fistula repair, and pilonidal sinus excision, where the saddle block technique with hyperbaric bupivacaine provides targeted perineal anesthesia.

The choice of hyperbaric over isobaric (plain) bupivacaine for spinal anesthesia is an important clinical decision. Multiple randomized controlled trials and systematic reviews have demonstrated that hyperbaric bupivacaine offers several advantages: faster onset of sensory and motor block, more predictable and reliable block levels, better operating conditions, and lower rates of block failure compared with isobaric formulations. A Cochrane systematic review comparing hyperbaric and isobaric spinal bupivacaine found that hyperbaric solutions produced more consistent and predictable spread of anesthesia, supporting their preferred use in clinical practice, particularly for cesarean sections and other procedures requiring a well-defined and reliable block level.

What Should You Know Before Receiving Bupivacaine Spinal Tung Aguettant?

Spinal anesthesia with bupivacaine is a well-established and safe procedure when performed by experienced practitioners on appropriately selected patients. However, like all forms of regional anesthesia, it carries specific risks that must be carefully weighed against the benefits for each individual patient. Your anesthesiologist will conduct a thorough pre-anesthetic assessment to determine whether spinal anesthesia is appropriate for you and to identify any factors that might increase your risk of complications.

Contraindications

Bupivacaine Spinal Tung Aguettant must not be used in the following circumstances:

• Known hypersensitivity: Allergy to bupivacaine, any other amide-type local anesthetic (such as lidocaine, ropivacaine, mepivacaine, or prilocaine), or any of the excipients in the formulation.
• Coagulation disorders: Active or clinically significant coagulopathy, thrombocytopenia (low platelet count), or therapeutic anticoagulation. These conditions significantly increase the risk of spinal hematoma, which can lead to permanent paralysis if not diagnosed and treated promptly.
• Infection at the injection site: Skin infection, abscess, or cellulitis at or near the intended lumbar puncture site, as this could introduce bacteria into the spinal canal.
• Systemic sepsis or bacteremia: Active systemic infection carries a risk of seeding bacteria to the meninges, potentially causing meningitis or epidural abscess.
• Severe hypovolemia or shock: Patients who are significantly dehydrated or in circulatory shock, as the sympathetic block produced by spinal anesthesia can cause dangerous cardiovascular collapse in these patients.
• Raised intracranial pressure: Conditions causing elevated intracranial pressure, as lumbar puncture can precipitate brainstem herniation.
• Severe spinal deformities: Major spinal abnormalities that make lumbar puncture technically impossible or extremely hazardous.

Warnings and Precautions

Several conditions require special caution and careful risk-benefit assessment when considering spinal anesthesia with bupivacaine:

• Cardiovascular disease: Patients with fixed cardiac output states (such as aortic stenosis, mitral stenosis, or hypertrophic obstructive cardiomyopathy) may not be able to compensate for the vasodilation and hypotension caused by sympathetic blockade. Patients with heart block or significant arrhythmias also require careful evaluation.
• Pre-existing neurological disease: Conditions such as multiple sclerosis, peripheral neuropathy, or spinal cord pathology may be relative contraindications, as it can be difficult to distinguish between pre-existing deficits and potential complications of the spinal block.
• Elderly patients: Older adults are more susceptible to the cardiovascular effects of spinal anesthesia, particularly hypotension. Lower doses are typically required, and careful fluid management and vasopressor support should be planned.
• Anticoagulant and antiplatelet therapy: Patients taking blood-thinning medications require careful timing of the spinal injection relative to their anticoagulant doses. International guidelines (ASRA/ESRA) provide specific recommendations for minimum time intervals between anticoagulant administration and neuraxial procedures.
• Hepatic impairment: Bupivacaine is metabolized by the liver. While systemic absorption from intrathecal injection is minimal, patients with severe liver disease may have altered drug handling.

Pregnancy and Breastfeeding

Bupivacaine is one of the most extensively studied drugs in obstetric anesthesia and is widely considered safe for use during pregnancy when administered for spinal anesthesia at standard intrathecal doses. Hyperbaric bupivacaine is the most commonly used agent for spinal anesthesia for cesarean section worldwide, and decades of clinical experience support its safety profile in this setting.

When administered intrathecally, the dose of bupivacaine is very small (typically 10–12.5 mg) and systemic absorption is minimal. However, bupivacaine does cross the placenta, and high systemic levels could potentially affect the fetus. At standard spinal anesthetic doses, fetal effects are generally minimal and clinically insignificant. Neonatal Apgar scores and neurobehavioral assessments are typically normal following cesarean delivery under spinal anesthesia with bupivacaine.

Regarding breastfeeding, bupivacaine is excreted in breast milk in very small quantities. Given the small intrathecal dose and the low oral bioavailability of bupivacaine, the amount transferred to the nursing infant is negligible and not expected to cause any adverse effects. Breastfeeding can generally be continued immediately after spinal anesthesia with bupivacaine.

How Does Bupivacaine Spinal Tung Aguettant Interact with Other Drugs?

Drug interactions with intrathecal bupivacaine differ from those seen with systemic (intravenous or large-volume local infiltration) administration because the intrathecal dose is very small and systemic absorption is minimal. Nevertheless, several important interactions must be considered by the anesthesiologist when planning spinal anesthesia.

The most critical interaction is not a pharmacological drug-drug interaction in the traditional sense, but rather the interaction between anticoagulant/antiplatelet medications and the spinal needle insertion itself. This interaction carries the risk of spinal hematoma, a rare but potentially devastating complication that can lead to permanent paralysis if not promptly diagnosed and surgically evacuated.

Major Interactions

The most critical interactions that require absolute attention are those involving anticoagulant and antiplatelet therapy. The American Society of Regional Anesthesia (ASRA) and the European Society of Regional Anaesthesia (ESRA) have published comprehensive guidelines specifying the minimum time intervals that must be observed between the last dose of various anticoagulants and the performance of neuraxial procedures. For example, low-molecular-weight heparin should be discontinued at least 12 hours (prophylactic dose) or 24 hours (therapeutic dose) before spinal anesthesia. Direct oral anticoagulants such as rivaroxaban and apixaban require at least 72 hours of discontinuation. These timing intervals are critical for patient safety and are regularly updated as new evidence emerges.

Minor Interactions

Several medications produce minor or manageable interactions when used alongside intrathecal bupivacaine. Beta-blockers may blunt the compensatory tachycardia that normally helps maintain blood pressure during spinal-induced sympathectomy, potentially worsening hypotension. ACE inhibitors and angiotensin receptor blockers may impair the renin-angiotensin response to hypotension. These interactions are generally manageable with appropriate fluid administration and vasopressor support. The anesthesiologist will take all current medications into account when planning the anesthetic technique and preparing for potential hemodynamic changes.

What Is the Correct Dosage of Bupivacaine Spinal Tung Aguettant?

Bupivacaine Spinal Tung Aguettant is exclusively administered by qualified anesthesiologists in hospital operating theaters or procedure rooms. The dose is never standardized but rather individually tailored to each patient and each surgical procedure. Several factors influence the dose selection, including the type and expected duration of surgery, the required dermatomal level of block, the patient's age, height, weight, physical status, and any coexisting medical conditions. The anesthesiologist draws the required volume from the ampoule using a sterile technique and injects it into the intrathecal space through a spinal needle, typically at the L3–L4 or L4–L5 intervertebral space.

Adults

For cesarean section, the dose is frequently combined with intrathecal adjuvants such as fentanyl (15–25 micrograms) or morphine (100–200 micrograms) to improve the quality of intraoperative anesthesia and provide postoperative analgesia. The addition of intrathecal opioids allows a lower dose of bupivacaine to be used, which can reduce the severity of hypotension while maintaining adequate surgical anesthesia.

Children

Spinal anesthesia with bupivacaine is used in pediatric patients, although less commonly than in adults. It is particularly useful in neonates and infants undergoing lower abdominal or lower extremity surgery, where it avoids the risks associated with general anesthesia, particularly in ex-premature infants at risk of postoperative apnea. Dosage in children is weight-based and varies by age group:

• Neonates and infants (< 5 kg): 0.4–0.5 mg/kg (0.08–0.1 ml/kg)
• Infants (5–15 kg): 0.3–0.4 mg/kg (0.06–0.08 ml/kg)
• Children (> 15 kg): 0.2–0.3 mg/kg (0.04–0.06 ml/kg), up to the adult dose

Pediatric spinal anesthesia requires specialized training and equipment, and the pharmacokinetics differ from adults (larger CSF volume relative to body weight, higher cardiac output resulting in faster absorption and shorter duration). These procedures should only be performed by anesthesiologists experienced in pediatric regional anesthesia.

Elderly

Elderly patients generally require reduced doses of intrathecal bupivacaine compared with younger adults. This is due to several age-related physiological changes: decreased volume of cerebrospinal fluid, reduced cross-sectional area of the spinal canal due to degenerative changes, increased sensitivity to the cardiovascular effects of sympathetic blockade, and slower metabolism and elimination of the drug. Dose reductions of 20–40% are commonly recommended in patients over 70 years of age. For example, a typical dose for a lower limb procedure in an elderly patient might be 7.5–10 mg rather than the 10–15 mg used in a younger adult. Careful titration and attentive hemodynamic monitoring are essential.

Missed Dose

The concept of a missed dose does not apply to Bupivacaine Spinal Tung Aguettant, as it is a single-injection medication administered by the anesthesiologist at the time of surgery. It is not a medication that patients take at home on a regular schedule.

Overdose

Overdose of intrathecal bupivacaine is a serious and potentially life-threatening situation that manifests as an excessively high or total spinal block. Symptoms of a high spinal block include progressive numbness and weakness extending above the intended level, difficulty breathing (due to paralysis of intercostal muscles and diaphragm), severe hypotension, profound bradycardia, and loss of consciousness. In the most severe cases (total spinal block), complete respiratory arrest and cardiovascular collapse can occur.

Treatment of intrathecal bupivacaine overdose is supportive and symptomatic. Immediate management includes securing the airway with endotracheal intubation and mechanical ventilation, aggressive intravenous fluid administration, and vasopressor support (typically ephedrine, phenylephrine, or epinephrine/adrenaline) to maintain blood pressure. Atropine is used to treat bradycardia. The effects of the high block will gradually resolve as the local anesthetic is absorbed and metabolized, typically over 2–4 hours. In the event of systemic bupivacaine toxicity (which is extremely rare with intrathecal administration due to the small doses used), intravenous lipid emulsion (Intralipid) therapy should be administered according to established protocols.

What Are the Side Effects of Bupivacaine Spinal Tung Aguettant?

Side effects of spinal anesthesia with bupivacaine can be broadly categorized into those directly caused by the pharmacological action of the drug (sympathetic blockade and nerve block) and those related to the spinal injection procedure itself. Most side effects are transient and resolve completely as the block wears off. Your anesthesiologist will actively monitor you throughout the procedure and in the immediate postoperative period to detect and treat any adverse effects promptly.

It is important to understand that many of the “side effects” listed below are predictable physiological consequences of spinal blockade rather than unexpected adverse reactions. For example, some degree of hypotension occurs in the majority of patients receiving spinal anesthesia and is anticipated, monitored, and treated as part of routine anesthetic management.

Post-dural puncture headache (PDPH) deserves special mention as it is one of the most common complications discussed with patients before spinal anesthesia. PDPH typically presents as a severe positional headache that worsens when sitting or standing and improves when lying flat. It usually develops within 24–48 hours after the procedure and resolves spontaneously within one to two weeks. Risk factors include younger age, female sex, pregnancy, and the use of larger-gauge spinal needles. The use of small-gauge pencil-point (atraumatic) needles has significantly reduced the incidence of PDPH. Treatment includes bed rest, hydration, caffeine, analgesics, and in persistent cases, an epidural blood patch (injection of the patient's own blood into the epidural space to seal the dural hole), which has a success rate of approximately 70–90%.

How Should You Store Bupivacaine Spinal Tung Aguettant?

Bupivacaine Spinal Tung Aguettant is a sterile, preservative-free solution supplied in single-use glass ampoules. As a hospital-only medication, storage is managed entirely by the hospital pharmacy and the anesthetic department. The following storage conditions apply:

• Temperature: Store below 25°C (77°F). Do not freeze. Freezing can damage the ampoule and compromise the sterility of the solution.
• Light protection: Store in the original packaging to protect from light. Bupivacaine solutions can degrade with prolonged light exposure.
• Single use: Each ampoule is intended for single use only. Any unused solution remaining after the procedure must be discarded. The solution does not contain preservatives, so microbial contamination is a risk if the opened ampoule is stored.
• Visual inspection: Before use, the solution should be inspected visually. It should be clear and colorless. Do not use if the solution appears cloudy, discolored, or contains visible particles.
• Shelf life: Do not use after the expiration date printed on the ampoule and outer packaging. The expiration date refers to the last day of that month.

Patients undergoing spinal anesthesia with this medication do not need to worry about storage or handling, as all preparation is performed by trained medical staff in a sterile environment. The medication is typically drawn up into a syringe immediately before administration and injected within a short time frame.

What Does Bupivacaine Spinal Tung Aguettant Contain?

Bupivacaine Spinal Tung Aguettant is a clear, colorless sterile solution supplied in glass ampoules, each containing 4 ml of solution (20 mg bupivacaine hydrochloride per ampoule). The complete composition is as follows:

Active Substance

• Bupivacaine hydrochloride: 5 mg per ml (equivalent to approximately 4.4 mg bupivacaine base per ml). Bupivacaine is an amide-type local anesthetic with a piperidine ring structure. It is the S(-)-enantiomer-enriched racemic mixture, meaning it contains both the R(+) and S(-) forms of the molecule. The S(-) enantiomer is associated with less cardiac toxicity compared to the R(+) form.

Excipients (Inactive Ingredients)

• Glucose (anhydrous): 80 mg per ml (8%). This is the key excipient that makes the solution hyperbaric (heavier than CSF). Glucose is a physiological substance that is readily metabolized by the body and does not contribute to the pharmacological effects of the anesthetic. The glucose concentration is the standard used in hyperbaric spinal anesthetic preparations worldwide.
• Sodium hydroxide and/or hydrochloric acid: Used in small quantities during manufacturing to adjust the pH of the solution to approximately 4.0–6.0. This pH range ensures stability of the bupivacaine molecule and is within the acceptable range for intrathecal injection.
• Water for injections: The pharmaceutical-grade sterile water used as the solvent for the formulation.

The solution is preservative-free, which is essential for intrathecal use. Preservatives such as methylparaben or parabens, which are found in some multi-dose local anesthetic formulations intended for other routes of administration, are neurotoxic and must never be injected intrathecally. The preservative-free nature of Bupivacaine Spinal Tung Aguettant ensures that it is safe for injection into the subarachnoid space.

The specific gravity of the finished solution is approximately 1.026 at 37°C, which is significantly higher than the specific gravity of human CSF (approximately 1.003–1.009). This density difference is what classifies the solution as “hyperbaric” and is the physical basis for the gravitational control of block spread that makes this formulation particularly useful in clinical anesthesia practice.